CA2751906C - Dispositif ultrasonore comprenant un moyen de generation d'un faisceau d'ultrasons presentant une forme de segment concave ayant une courbure unique - Google Patents
Dispositif ultrasonore comprenant un moyen de generation d'un faisceau d'ultrasons presentant une forme de segment concave ayant une courbure unique Download PDFInfo
- Publication number
- CA2751906C CA2751906C CA2751906A CA2751906A CA2751906C CA 2751906 C CA2751906 C CA 2751906C CA 2751906 A CA2751906 A CA 2751906A CA 2751906 A CA2751906 A CA 2751906A CA 2751906 C CA2751906 C CA 2751906C
- Authority
- CA
- Canada
- Prior art keywords
- eye
- transducers
- eye ring
- segment shape
- sawn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002604 ultrasonography Methods 0.000 title claims abstract description 63
- 238000011282 treatment Methods 0.000 claims abstract description 49
- 230000008397 ocular pathology Effects 0.000 claims abstract description 8
- 238000011269 treatment regimen Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 210000001508 eye Anatomy 0.000 description 121
- 208000010412 Glaucoma Diseases 0.000 description 32
- 210000004240 ciliary body Anatomy 0.000 description 32
- 238000000034 method Methods 0.000 description 31
- 238000001356 surgical procedure Methods 0.000 description 25
- 210000000695 crystalline len Anatomy 0.000 description 17
- 230000003902 lesion Effects 0.000 description 17
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 210000001742 aqueous humor Anatomy 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 210000001585 trabecular meshwork Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 208000002177 Cataract Diseases 0.000 description 8
- 208000002352 blister Diseases 0.000 description 7
- 210000000795 conjunctiva Anatomy 0.000 description 7
- 210000004087 cornea Anatomy 0.000 description 7
- 210000003786 sclera Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000007943 implant Substances 0.000 description 6
- 210000001328 optic nerve Anatomy 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- 210000002159 anterior chamber Anatomy 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000004410 intraocular pressure Effects 0.000 description 5
- 239000008177 pharmaceutical agent Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 4
- 230000004509 aqueous humor production Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 206010014801 endophthalmitis Diseases 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000001747 pupil Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 2
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010012565 Developmental glaucoma Diseases 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- 229960000722 brinzolamide Drugs 0.000 description 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 2
- 208000029444 double vision Diseases 0.000 description 2
- 230000004406 elevated intraocular pressure Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 208000011323 eye infectious disease Diseases 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- AQOKCDNYWBIDND-ABRBVVEGSA-N 5-trans-17-phenyl trinor Prostaglandin F2alpha ethyl amide Chemical compound CCNC(=O)CCC\C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-ABRBVVEGSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010018325 Congenital glaucomas Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010051283 Fluid imbalance Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000006336 Juvenile glaucoma Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229940003677 alphagan Drugs 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229940098085 betagan Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 229940099238 diamox Drugs 0.000 description 1
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 1
- 229960000966 dipivefrine Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000028507 juvenile open angle glaucoma Diseases 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- DNTDOBSIBZKFCP-YDALLXLXSA-N levobunolol hydrochloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OC[C@@H](O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-YDALLXLXSA-N 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920002529 medical grade silicone Polymers 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229940113006 travatan Drugs 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- 229940108420 trusopt Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00736—Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments
- A61F9/00745—Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments using mechanical vibrations, e.g. ultrasonic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Radiology & Medical Imaging (AREA)
- Surgical Instruments (AREA)
Abstract
La présente invention porte sur un dispositif de traitement d'une pathologie oculaire, le dispositif comprenant au moins un anneau oculaire (1) dans lequel l'extrémité proximale dudit anneau oculaire (1) est appropriée pour être appliquée sur le globe et un moyen (2, 17) de génération d'un faisceau ultrasonore fixé sur l'extrémité distale de l'anneau oculaire (1), ledit moyen de génération de faisceau ultrasonore présentant une forme de segment concave conformée le long d'une courbure unique correspondant à une direction unique dans laquelle la concavité est conçue pour être en accord avec le globe oculaire.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2009/051892 | 2009-02-18 | ||
| PCT/EP2009/051892 WO2009103721A1 (fr) | 2008-02-19 | 2009-02-18 | Procédé de traitement d'une pathologie oculaire par application d'ultrasons à haute intensité concentrés et dispositif dans ce but |
| PCT/EP2009/060678 WO2010094349A1 (fr) | 2009-02-18 | 2009-08-18 | Dispositif ultrasonore comprenant un moyen de génération d'un faisceau d'ultrasons présentant une forme de segment concave ayant une courbure unique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2751906A1 CA2751906A1 (fr) | 2010-08-26 |
| CA2751906C true CA2751906C (fr) | 2018-03-27 |
Family
ID=41683368
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2751906A Active CA2751906C (fr) | 2009-02-18 | 2009-08-18 | Dispositif ultrasonore comprenant un moyen de generation d'un faisceau d'ultrasons presentant une forme de segment concave ayant une courbure unique |
| CA2751908A Abandoned CA2751908A1 (fr) | 2009-02-18 | 2009-08-26 | Procede de traitement d'une pathologie oculaire par application d'ultrasons au trabecule corneo-scleral et son dispositif |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2751908A Abandoned CA2751908A1 (fr) | 2009-02-18 | 2009-08-26 | Procede de traitement d'une pathologie oculaire par application d'ultrasons au trabecule corneo-scleral et son dispositif |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR101638140B1 (fr) |
| AU (1) | AU2009340220B2 (fr) |
| CA (2) | CA2751906C (fr) |
| IL (1) | IL214456A0 (fr) |
| RU (1) | RU2515509C2 (fr) |
| WO (2) | WO2010094349A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11771596B2 (en) * | 2010-05-10 | 2023-10-03 | Ramot At Tel-Aviv University Ltd. | System and method for treating an eye |
| US20130218145A1 (en) * | 2010-05-10 | 2013-08-22 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | System and method for treating an eye |
| FR2973250B1 (fr) * | 2011-03-29 | 2015-01-02 | Edap Tms France | Sonde de therapie pour le traitement de tissus par l'intermediaire d'ondes ultrasonores focalisees croisees |
| FR2973685B1 (fr) * | 2011-04-05 | 2014-11-28 | Eye Tech Care | Dispositif de therapie oculaire par ultrasons a reflecteur |
| DE102011116368A1 (de) * | 2011-10-17 | 2013-04-18 | Carl Zeiss Meditec Ag | Vorrichtung und Verfahren zur extrakapsulären chirurgischen Kataraktbehandlung |
| FR2983700B1 (fr) * | 2011-12-08 | 2014-03-07 | Eye Tech Care | Dispositif de succion pour le traitement d'une pathologie oculaire |
| DE102012019165B3 (de) | 2012-09-28 | 2013-07-18 | Carl Zeiss Meditec Ag | Handstück für die Phakoemulsifikation einer Augenlinse |
| RU2603718C2 (ru) * | 2015-04-17 | 2016-11-27 | ЗАКРЫТОЕ АКЦИОНЕРНОЕ ОБЩЕСТВО "ОПТИМЕДСЕРВИС" (ЗАО "Оптимедсервис") | Ультразвуковой инструмент факоэмульсификатора с трехмерными колебаниями |
| KR102446920B1 (ko) * | 2020-10-27 | 2022-09-23 | 웰스메디텍 주식회사 | 마이봄샘 기능부전의 증상 완화를 위한 초음파 처리 장치 |
| EP4297867A1 (fr) * | 2021-02-26 | 2024-01-03 | Institut national de la santé et de la recherche médicale (INSERM) | Transducteurs ultrasonores thérapeutiques pour émission d'ondes ultrasonores focalisées |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4484569A (en) * | 1981-03-13 | 1984-11-27 | Riverside Research Institute | Ultrasonic diagnostic and therapeutic transducer assembly and method for using |
| DE3932967A1 (de) * | 1989-10-03 | 1991-04-11 | Wolf Gmbh Richard | Ultraschall-stosswellenwandler |
| DE4430720A1 (de) * | 1993-12-21 | 1995-06-22 | Zeiss Carl Fa | Vorrichtung und Verfahren zur Laser-Cyclophotokoagulation |
| US5591127A (en) * | 1994-01-28 | 1997-01-07 | Barwick, Jr.; Billie J. | Phacoemulsification method and apparatus |
| US5645530A (en) * | 1995-08-28 | 1997-07-08 | Alcon Laboratories, Inc. | Phacoemulsification sleeve |
| US6419648B1 (en) * | 2000-04-21 | 2002-07-16 | Insightec-Txsonics Ltd. | Systems and methods for reducing secondary hot spots in a phased array focused ultrasound system |
| US8162858B2 (en) * | 2004-12-13 | 2012-04-24 | Us Hifu, Llc | Ultrasonic medical treatment device with variable focal zone |
| EP1738725A1 (fr) * | 2005-06-30 | 2007-01-03 | Wavelight Laser Technologie AG | Appareil de chirurgie oculaire |
| US20070239011A1 (en) * | 2006-01-13 | 2007-10-11 | Mirabilis Medica, Inc. | Apparatus for delivering high intensity focused ultrasound energy to a treatment site internal to a patient's body |
| FR2906165B1 (fr) * | 2006-09-27 | 2009-01-09 | Corneal Ind Soc Par Actions Si | Systeme d'emission d'ultrasons et machine de traitement par ultrasons integrant ledit systeme |
| US8323296B2 (en) * | 2007-03-15 | 2012-12-04 | Boris Malyugin | Ring used in a small pupil phacoemulsification procedure |
| US20080275370A1 (en) * | 2007-05-01 | 2008-11-06 | Mcintyre Jon T | Apparatus and method for treating visual disorders |
-
2009
- 2009-08-18 RU RU2011138181/14A patent/RU2515509C2/ru active
- 2009-08-18 AU AU2009340220A patent/AU2009340220B2/en active Active
- 2009-08-18 WO PCT/EP2009/060678 patent/WO2010094349A1/fr active Application Filing
- 2009-08-18 KR KR1020117020828A patent/KR101638140B1/ko active IP Right Grant
- 2009-08-18 CA CA2751906A patent/CA2751906C/fr active Active
- 2009-08-26 WO PCT/EP2009/061014 patent/WO2010094353A1/fr active Application Filing
- 2009-08-26 CA CA2751908A patent/CA2751908A1/fr not_active Abandoned
-
2011
- 2011-08-04 IL IL214456A patent/IL214456A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009340220A1 (en) | 2011-09-01 |
| AU2009340220B2 (en) | 2013-07-18 |
| WO2010094353A1 (fr) | 2010-08-26 |
| RU2011138181A (ru) | 2013-03-27 |
| CA2751906A1 (fr) | 2010-08-26 |
| WO2010094349A1 (fr) | 2010-08-26 |
| IL214456A0 (en) | 2011-09-27 |
| KR101638140B1 (ko) | 2016-07-11 |
| KR20110126662A (ko) | 2011-11-23 |
| RU2515509C2 (ru) | 2014-05-10 |
| CA2751908A1 (fr) | 2010-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9931245B2 (en) | High intensity focused ultrasound device with a concave segment shaped transducers for treatment of ocular pathology | |
| CA2751906C (fr) | Dispositif ultrasonore comprenant un moyen de generation d'un faisceau d'ultrasons presentant une forme de segment concave ayant une courbure unique | |
| AU2009351378B2 (en) | Parameters for an ultrasound device comprising means to generate high intensity ultrasound beam | |
| EP2398432B1 (fr) | Dispositif pour le traitement d'une pathologie oculaire par l'application d'ultrasons haute intensité concentrés | |
| WO2011083358A1 (fr) | Dispositif pour traiter une pathologie oculaire en appliquant des doses d'énergie laser | |
| AU2009216751B2 (en) | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140723 |